CA2309688C - Penetration enhancing and irritation reducing systems - Google Patents
Penetration enhancing and irritation reducing systems Download PDFInfo
- Publication number
- CA2309688C CA2309688C CA002309688A CA2309688A CA2309688C CA 2309688 C CA2309688 C CA 2309688C CA 002309688 A CA002309688 A CA 002309688A CA 2309688 A CA2309688 A CA 2309688A CA 2309688 C CA2309688 C CA 2309688C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- accordance
- weight
- present
- glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000007794 irritation Effects 0.000 title claims description 31
- 230000035515 penetration Effects 0.000 title abstract description 25
- 230000002708 enhancing effect Effects 0.000 title description 11
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 200
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 67
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 43
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 43
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 43
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 43
- 239000005642 Oleic acid Substances 0.000 claims description 43
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 43
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 43
- 229960003604 testosterone Drugs 0.000 claims description 37
- 239000013543 active substance Substances 0.000 claims description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 239000003349 gelling agent Substances 0.000 claims description 30
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 24
- 229920002125 Sokalan® Polymers 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- -1 poly(1-carboxylethylene) Polymers 0.000 claims description 13
- 239000003638 chemical reducing agent Substances 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 238000011200 topical administration Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 229960001631 carbomer Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 229930182833 estradiol Natural products 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 150000003515 testosterones Chemical class 0.000 claims description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 claims 2
- 229960001712 testosterone propionate Drugs 0.000 claims 2
- 150000002159 estradiols Chemical class 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000012377 drug delivery Methods 0.000 abstract description 10
- 230000009467 reduction Effects 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 63
- 210000003491 skin Anatomy 0.000 description 44
- 235000021313 oleic acid Nutrition 0.000 description 39
- 235000019441 ethanol Nutrition 0.000 description 32
- 231100000475 skin irritation Toxicity 0.000 description 13
- 206010040880 Skin irritation Diseases 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 230000036556 skin irritation Effects 0.000 description 12
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 11
- 229940055577 oleyl alcohol Drugs 0.000 description 11
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003961 penetration enhancing agent Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000013271 transdermal drug delivery Methods 0.000 description 4
- 206010002261 Androgen deficiency Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 239000004792 Prolene Substances 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229940075509 carbomer 1342 Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229940007266 testosterone topical gel Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs a nd with the reduction of skin imitation that often accompanies transdermal and topical drug delivery.
Description
PENETRATION ENHANCING AND IRRITATION REDUCING SYSTEMS
FIELD OF INVENTION
This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and to reduction of the skin irritation that often accompanies transdermally and topically applied drug delivery.
BACKGROUND OF THE INVENTION
During the past decade, the feasibility of the dermal route for systemic drug delivery has been established. Transdermal therapeutic systems include those containing scopolamine, glyceryl trinitrate, clonidine, fentanyl, nicotine and estradiol.
However, one drawback with drugs applied to the skin or mucous membrane is that they frequently cause irritation. Additionally, many of the necessary components of topical, transdermal, and transmucosal formulations and delivery devices, such as solubilizing agents, suspending agents, dispersing agents, preservatives, animal and vegetable fats, oils, or waxes, stabilizing agents, thickening or gelling agents, buffering agents, adhesive agents, and, particularly, penetration enhancing agents, are irritating alone or in combination. However, in the absence of penetration enhancing agents, few drugs are capable of penetrating the skin or mucous membranes in therapeutically effective concentrations. Typically, using penetration enhancing compounds, processes or devices to increase drug penetration solves this problem. Included among these are chemical enhancers, iontophoresis, sonophoresis, and various delivery devices.
In most instances, penetration enhancement usually results in unwanted irritation. Many transdermal and topical products show high incidences of adverse skin reactions such as scaling, pruritic erythema, and vesicobollous irritant and allergic contact dermatitis. This is particularly true for topical and transdermal testosterone products currently on the market. Formulations comprised of combinations of ingredients of the same type instead of only one ingredient of that type, such as using a combination of two solvents instead of just one solvent, have been reported to lessen irritation without lowering drug permeation. This approach has also been applied to penetration enhancing agents. In particular, the use of glycerol, polyglycerol ethers, or dexpanthenol in combination with other penetration enhancing agents has been reported to lessen irritation. Using mixtures of penetration enhancers of different polarities and modes of action has also been reported to increase drug permeability without necessitating the use of higher concentrations of irritating penetration enhancers. The problem has also been approached by the additional inclusion of non-irritating ingredients such as glycerin.
U.S. Patent No. 5,760,096, which issued to Thornfeldt et al. on June 2, 199$, discloses a penetration enhancing system based on the use of various combinations of known penetration enhancing excipients. One type of penetration system disclosed combines an alcohol and a glycol; at glycol: alcohol weight ratios of about 1:0.1 to about 1:10, with one or more excipients categorized as surfactants, branched chain fatty acid esters, or membrane fluidizers.
In addition, U.S. Patent No. 4,863,970, which issued to Patel er al. on 1 S September 5, 1989, discloses a penetration-enhancing binary mixture of a cell-envelope-disordering compound and a lower alcohol. The binary mixtures can optionally contain inert ingredients that are soluble within the enhancer compositions. Neither Thomfeldt et al. nor Patel et al. teach or disclose the beneficial use of oleic acid in favor of oleyl alcohol. In addition, the use of~a gelling agent in combination with oleic acid is not ?0 disclosed.
Ultimately, the success of transdermal systems depends on the ability of the drug to~permeate the skin in sufficient quantities to achieve the desired therapeutic effect. However, the transdermal system's ability for skin permeation is tempered by the irritation side effect that it can cause. There is a need in the art for a transdermal 2S therapeutic system that has good penetration, but that has little unwanted skin and mucous membrane irritation. The present invention fulfills this and other needs.
2a SUNINIARY OF THE INVENTION
Various embodiments of this invention provide a membrane fluidizer composition for use in preparation of a medicament for topical administration of an active agent which is a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof, said composition comprising: (i) oleic acid; (ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
This invention also provides the use of the aforementioned composition for preparation of a medicament for topical administration of a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof, and for treatment of a patient who would benefit from administration of a sex hormone.
Various embodiments of this invention provide a method of making a pharmaceutical composition for topical administration, said method comprising mixing a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof with the aforementioned composition, and adjusting pH of the resulting mixture to a pH from about 3 to about 6. Preferably, the pH is adjusted to a pH from about 5 to about 6.
Various embodiments of this invention provide a pharmaceutical composition for topical administration comprising: (a) an active agent which is a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof; and (b) a penetration-enhancing system comprising: (i) oleic acid;
(ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
This invention also provides the use of the aforementioned pharmaceutical composition for preparation of a medicament for topical administration and for treatment of a patient who would benefit from administration of a sex hormone.
The compositions of the present invention relate to a penetration enhancing system (PES) that can be utilized in many types of products for topical or transdermal application, that include, but are not limited to, solutions, creams, lotions, ointments, gels, aerosols and patch devices. In certain aspects, the present invention relates to a composition for topical application having penetration-enhancing properties, the composition comprising an active agent; and a penetration-enhancing system that comprises oleic acid; a C1-Ca alcohol; and a glycol. Optionally, the composition further comprises a gelling agent. In preferred embodiments, the gelling agent is CARBOPOL~
which is a polyacryiic acid. In certain embodiments, the preferred active ingredient is testosterone or a testosterone derivative.
The penetration enhancing system of the present invention effectively enhances delivery of transdermally and/or topically active substances, while surprisingly reducing skin irritation caused by the application of irritating substances to the skin. The penetration enhancing system of the present invention can also be used for mucosal delivery.
In another aspect, the present invention relates to a method for administering a topically or systemically active agent, the method comprising:
topically administering to a mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a C,-Ca alcohol;
and (iii) a glycol. Optionally, the penetration-enhancing system further comprises (iv) a gelling agent. In certain preferred embodiments, the method relates to treatment of conditions related to testosterone deficiency.
In yet another aspect, the present invention relates to a method of reducing inflammation associated with topical application of an active agent, the method comprising: topically administering to a terrestrial mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a Ci-Ca alcohol; and (iii) a glycol. In certain embodiments, the penetration-enhancing system further comprises (iv) a gelling agent. Typically, the inflammation is associated with the skin.
Further combinations, compositions and aspects of the present invention will be apparent with the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates the cumulative testosterone levels in a receiver reservoir delivered from three topical formulations compared to a commercial patch gel across excised pig skin.
Figure 2 illustrates the influence of solution pH and concentration of testosterone of the formulations of the present invention.
FIELD OF INVENTION
This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and to reduction of the skin irritation that often accompanies transdermally and topically applied drug delivery.
BACKGROUND OF THE INVENTION
During the past decade, the feasibility of the dermal route for systemic drug delivery has been established. Transdermal therapeutic systems include those containing scopolamine, glyceryl trinitrate, clonidine, fentanyl, nicotine and estradiol.
However, one drawback with drugs applied to the skin or mucous membrane is that they frequently cause irritation. Additionally, many of the necessary components of topical, transdermal, and transmucosal formulations and delivery devices, such as solubilizing agents, suspending agents, dispersing agents, preservatives, animal and vegetable fats, oils, or waxes, stabilizing agents, thickening or gelling agents, buffering agents, adhesive agents, and, particularly, penetration enhancing agents, are irritating alone or in combination. However, in the absence of penetration enhancing agents, few drugs are capable of penetrating the skin or mucous membranes in therapeutically effective concentrations. Typically, using penetration enhancing compounds, processes or devices to increase drug penetration solves this problem. Included among these are chemical enhancers, iontophoresis, sonophoresis, and various delivery devices.
In most instances, penetration enhancement usually results in unwanted irritation. Many transdermal and topical products show high incidences of adverse skin reactions such as scaling, pruritic erythema, and vesicobollous irritant and allergic contact dermatitis. This is particularly true for topical and transdermal testosterone products currently on the market. Formulations comprised of combinations of ingredients of the same type instead of only one ingredient of that type, such as using a combination of two solvents instead of just one solvent, have been reported to lessen irritation without lowering drug permeation. This approach has also been applied to penetration enhancing agents. In particular, the use of glycerol, polyglycerol ethers, or dexpanthenol in combination with other penetration enhancing agents has been reported to lessen irritation. Using mixtures of penetration enhancers of different polarities and modes of action has also been reported to increase drug permeability without necessitating the use of higher concentrations of irritating penetration enhancers. The problem has also been approached by the additional inclusion of non-irritating ingredients such as glycerin.
U.S. Patent No. 5,760,096, which issued to Thornfeldt et al. on June 2, 199$, discloses a penetration enhancing system based on the use of various combinations of known penetration enhancing excipients. One type of penetration system disclosed combines an alcohol and a glycol; at glycol: alcohol weight ratios of about 1:0.1 to about 1:10, with one or more excipients categorized as surfactants, branched chain fatty acid esters, or membrane fluidizers.
In addition, U.S. Patent No. 4,863,970, which issued to Patel er al. on 1 S September 5, 1989, discloses a penetration-enhancing binary mixture of a cell-envelope-disordering compound and a lower alcohol. The binary mixtures can optionally contain inert ingredients that are soluble within the enhancer compositions. Neither Thomfeldt et al. nor Patel et al. teach or disclose the beneficial use of oleic acid in favor of oleyl alcohol. In addition, the use of~a gelling agent in combination with oleic acid is not ?0 disclosed.
Ultimately, the success of transdermal systems depends on the ability of the drug to~permeate the skin in sufficient quantities to achieve the desired therapeutic effect. However, the transdermal system's ability for skin permeation is tempered by the irritation side effect that it can cause. There is a need in the art for a transdermal 2S therapeutic system that has good penetration, but that has little unwanted skin and mucous membrane irritation. The present invention fulfills this and other needs.
2a SUNINIARY OF THE INVENTION
Various embodiments of this invention provide a membrane fluidizer composition for use in preparation of a medicament for topical administration of an active agent which is a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof, said composition comprising: (i) oleic acid; (ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
This invention also provides the use of the aforementioned composition for preparation of a medicament for topical administration of a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof, and for treatment of a patient who would benefit from administration of a sex hormone.
Various embodiments of this invention provide a method of making a pharmaceutical composition for topical administration, said method comprising mixing a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof with the aforementioned composition, and adjusting pH of the resulting mixture to a pH from about 3 to about 6. Preferably, the pH is adjusted to a pH from about 5 to about 6.
Various embodiments of this invention provide a pharmaceutical composition for topical administration comprising: (a) an active agent which is a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof; and (b) a penetration-enhancing system comprising: (i) oleic acid;
(ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
This invention also provides the use of the aforementioned pharmaceutical composition for preparation of a medicament for topical administration and for treatment of a patient who would benefit from administration of a sex hormone.
The compositions of the present invention relate to a penetration enhancing system (PES) that can be utilized in many types of products for topical or transdermal application, that include, but are not limited to, solutions, creams, lotions, ointments, gels, aerosols and patch devices. In certain aspects, the present invention relates to a composition for topical application having penetration-enhancing properties, the composition comprising an active agent; and a penetration-enhancing system that comprises oleic acid; a C1-Ca alcohol; and a glycol. Optionally, the composition further comprises a gelling agent. In preferred embodiments, the gelling agent is CARBOPOL~
which is a polyacryiic acid. In certain embodiments, the preferred active ingredient is testosterone or a testosterone derivative.
The penetration enhancing system of the present invention effectively enhances delivery of transdermally and/or topically active substances, while surprisingly reducing skin irritation caused by the application of irritating substances to the skin. The penetration enhancing system of the present invention can also be used for mucosal delivery.
In another aspect, the present invention relates to a method for administering a topically or systemically active agent, the method comprising:
topically administering to a mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a C,-Ca alcohol;
and (iii) a glycol. Optionally, the penetration-enhancing system further comprises (iv) a gelling agent. In certain preferred embodiments, the method relates to treatment of conditions related to testosterone deficiency.
In yet another aspect, the present invention relates to a method of reducing inflammation associated with topical application of an active agent, the method comprising: topically administering to a terrestrial mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a Ci-Ca alcohol; and (iii) a glycol. In certain embodiments, the penetration-enhancing system further comprises (iv) a gelling agent. Typically, the inflammation is associated with the skin.
Further combinations, compositions and aspects of the present invention will be apparent with the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates the cumulative testosterone levels in a receiver reservoir delivered from three topical formulations compared to a commercial patch gel across excised pig skin.
Figure 2 illustrates the influence of solution pH and concentration of testosterone of the formulations of the present invention.
DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS
In certain aspects, the present invention relates to transdermal and topical drug delivery. In particular, using this mode of drug delivery, enhancement of the penetration of topically applied drugs is typically accompanied by an increase in skin irntation. As such, in one aspect, the present invention relates~to a composition for topical application having penetration-enhancing properties, the composition comprising:
a) an active agent; b) a penetration-enhancing system comprising: (i) a membrane Iluidizer; (ii) a C1-Ca alcohol; and (iii) a glycol. In certain embodiments, the composition further comprises (iv) a gelling agent. This penetration enhancing system of the present invention increases transdermal and topical drug delivery while decreasing skin irritation, thereby allowing high levels of drug delivery to be achieved without causing unacceptable adverse skin reactions.
The active ingredients of the present invention can include all types of therapeutic drugs or other compounds. The active ingredients include both systemically active agents as well as topically active agents. Systemically active agents induce a biological response upon entering the blood stream. Topically active agents refer to compounds that induce a biologic response in the skin or mucous membrane.
Systemically active agents include, but are not limited to, anti-infectives such as antibiotics and antiviral agents, analgesics and analgesic combinations, anorexics and appetite suppressants, anthelmintics, anesthetics, antiarthritics, antiasthma agents, anticonvulsants, antidepressants, antidiabetic agents, antidiarrheals, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness agents, antinauseants, antineoplastics, antiparkinsonism agents, antipruritics, antipsychotics, antipyretics, antispasmodics, anticholinergics, sympathomimetics, xanthine derivatives, cardiovascular preparations including calcium channel blockers, beta Mockers, antiarrhythmics, antihypertensives, diuretics, vasodilators (general, coronary, peripheral and cerebral), central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, hormones, hypnotics, immunosuppressives, muscle relaxants, parasympatholytics, parasympathomimetics, psychostimulants, sedatives, tranquilizers, antioxidants, vitamins, minerals, other nutrients, and herbal extracts or preparations.
Topically active agents include, but are not limited to, anti-inflammatory agents, anti-infectives, analgesics, anesthetics, antihistamines, photoprotective agents, antineoplastics, antipruritics, neuropeptides, channel blockers, hydrocarbon compositions, hormones, vitamins, minerals, antioxidants, other nutrients, herbal extracts or preparations, and cosmetic ingredients. Certain agents listed above are active both systemically and in the skin and mucous membrane.
The amount of systemically and/or topically active agent included in the 5 formulation is subject to the degree to which penetration enhancement is achieved. When the increase in penetration is relatively large, lesser amounts of the active agent can be used. With these considerations, the appropriate amounts or concentrations in any given instance will be readily apparent to the skilled physician prescribing the formulation or to the formulator preparing the formulation for use by the lay person.
In a preferred embodiment, the active agent is a mammalian sex hormone, hormone derivative, or hormone mimetic. Examples include, but are not limited testosterone or estradiol. The active ingredient is present in the composition in about 0.1 to about 10 % weight to weight: Preferably, from about 0.1% to about S %, and more preferably, from about 1 % to about 2 % weight to weight of the composition.
The compositions of the present invention include oleic acid. Oleic acid (cis-9-octadecenoic acid) is a monounsaturated fatty acid. Oleic acid is present from about O.I % to about 10 % weight to weight of the composition, preferably it is present from about 0.1 % to about 5 % weight to weight of the composition. The ability of oleic acid to lessen the irritation caused by other penetration enhancing agents and/or other formulation components to a greater extent than oleyl alcohol has not been described previously. By adding oleic acid to the compositions of the present invention, such as testosterone formulations, the skin irritation caused by these formulations is markedly reduced. Surprisingly, the combination of oleic acid with a gelling agent, such as CARBOPOL~ (a polyacrylic acid), and/or other irritation reducing agents results in formulations that produce unexpectedly low levels of skin irritation.
Before the advent of the present invention, it was believed that oleic acid, oleyl alcohol and esters of oleic acid were all equal in their ability to enhance penetration and reduce skin irritation. Surprisingly, it has now been discovered that oleic acid is far superior to oleyl alcohol in its ability to reduce skin irritation. This is especially true when oleic acid is used in combination with a gelling agent.
In addition to oleic acid, the penetrating enhancing system of the present invention contains an alcohol. As used herein the term "alcohol" refers to a monohydric alcohol, preferably an aliphatic alcohol and more preferably a saturated monohydric aliphatic alcohol. Examples are methanol, ethanol, propanol, isopropanol, and octanol.
In the present invention, a Ci-C4 alcohol is preferred. These include, but are not limited to, ethanol, propanol, isopropanol and mixtures thereof. Mixtures include, for example, ethanol and isopropanol.
The compositions in accordance with the present invention contain an alcohol in about 5 % to about 55 % weight to weight of the composition.
Preferably, the alcohol is present from about 10 % to about 40 % weight to weight and more preferably, from about 25 % to about 35 % weight to weight of the composition.
In addition to oleic acid and an alcohol, the penetration-enhancing system of the present invention comprises a glycol. As used herein, the term "glycol"
refers to a polyhydric alcohol, preferably a dihydric alcohol. Examples are ethylene glycol, propylene glycol, butylene glycol and glycerol. Preferably, the glycol is ethylene glycol, propylene glycol, butylene glycol and mixtures thereof.
The compositions of the present invention contain a glycol in about 25 to about 55 % weight to weight of the composition. Preferably, the glycol content is from about 30 % to about 40 % weight to weight of the composition.
In addition, the compositions of the present invention optionally comprise a gelling agent. Formulations with a gelling agent in conjunction with oleic acid were tested. Formulations containing a gelling agent, for instance, CARBOPOL# 1342 (a polyacrylic acid), produced lower levels of skin irritation than did formulations containing no Gelling agent. These tests indicate that including a gelling agent in the PES
maintains the system's ability to enhance topical and transdermal drug delivery, while reducing irritation associated with topical or transdermai application. This finding is quite remarkable because the inclusion of lower alcohols is known to induce skin sensitization and was heretofore believed to be unsuitable as solvents for compounds applied to the skin. Surprisingly, including a gelling agent with oleic acid resulted in lower irritation levels than formulations with oleyl alcohol and a Gelling agent.
Suitable gelling agents of the present invention include, but are not limited to, Carbopol'1342, Carbopo1~940, Klucel~and Klucel HF. Synonyms for carbopol are carbomer, poly(1-carboxyethylene) or poly(acrylic acid). Those of skill in the art will know of other eeIIinG agents that are suitable to practice the present invention. The gelling went is present from about 1 % to about 10 % weight to weight of the 'Trade-mark composition. Preferably, the gelling agent is present from about 1 % to about 5 %, and more preferably, from about 1 % to about 3 % weight to weight of the composition.
The formulations in which the compositions of the present invention are incorporated in can assume any of a variety of dosage forms. Examples are creams, lotions, gels, ointments, suppositories, sprays, aerosols, buccal and sublingual tablets and various passive and active transdermal devices for absorption through the skin and mucous membranes.
The penetration enhancing compositions of this invention may constitute a small amount of the formulation or a large amount depending on which excipient composition is used, which systemically and/or topically active agent is used and the type of biological effect sought. The amount will be readily apparent to those skilled in the art, since the total amount of penetration enhancers will be approximately the same as those of the prior art. For example, when the potency of the penetration enhancement composition is greatly increased, lower quantities can be used.
In addition to the foregoing composition components, the compositions of the present invention can optionally contain other ingredients. For example, triethanolamine, can be added as a crosslinking agent. A preservative, such as betahydoxytoluene can be added. Other irritation reducing agents can be added.
In this regard, irritation reducing agents include, but are not limited to, glycerol.
In some instances, semi-solid testosterone formulations have been prepared with propylene glycol and/or butylene glycol as the glycol component, ethyl alcohol and/or isopropyl alcohol as the alcohol component. Preservatives, a cross-linking agent, and additional irritation reducing agents have been included in formulations prepared in accordance with this invention.
Various conditions and disorders are treatable, prevented, or promoted by the compositions of the present invention. Examples of conditions include, but are not limited to, treatment of conditions related to testosterone deficiency;
treatment of balanitis xerotic obliterans; treatment of lichen sclerosis et atrophicus; treatment of menopausal and postmenopausal symptoms and signs; prevention and/or reduction of aging related changes to skin and mucous membranes; prevention and/or reduction of skin pigmentation; prevention and/or reduction of skin roughness, wrinkles, furrows, fragility and/or atrophy; prevention and/or reduction of nail thinning and/or fracturing; prevention and/or reduction of hair thinning and/or fracturing; prevention and/or reduction of neoplasia of the skin, mucous membranes, other epithelia, and glands;
prevention and/or reduction of age-related bone demineralization; promotion of hair and/or nail growth;
promotion of increased muscle size and stamina; peversal of muscle wasting;
promotion of increased speed of reaction time and reversal of decreased reaction time;
promotion of increased growth of appendages and organism as a whole; prevention and/or reversal of xerosis; promotion of healing or as treatment for hemorrhoids or anal fissures.
As such, in another aspect, the present invention relates to a method for administering a topically or systemically active agent, the method comprising:
topically administering to a mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a C1-C4 alcohol;
and (iii) a glycol. In some embodiments, the penetration-enhancing system further comprises (iv) a gelling agent. In certain preferred embodiments, the method relates to treatment of conditions related to testosterone deficiency.
In yet another aspect, the present invention relates to a method of reducing inflammation associated with topical application of an active agent, the method comprising: topically administering to a mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a C~-Ca alcohol; and (iii) a glycol. In some embodiments, the penetration-enhancing system further comprises (iv) a gelling agent.
Subjects to whom the formulations can be administered are primarily mammals, including humans, pets, and livestock and other farm animals. The invention is of greatest interest in its application to humans. The term "topical administration" or "topical application" refers to directly layering or spreading upon epidermal tissue, especially outer skin or membrane, including the skin or membrane of the oral or vaginal cavities.
The site of application is dependent on many factors including, but not limited to, the amount of drug to be delivered, the extent of enhancement required, the irritation response manifested and the time of application. Thus, another important facet of this invention is the use of these compositions with drugs other than for example, testosterone, or to apply such formulations, or topical products in general, specifically to the soles of the feet, the palms of the hands or other immune-privileged sites of the body.
Also, the drugs, compositions or products may be administered later in the day or at night when the permeability at the site of application is higher.
WO 99/24041 PCT/US98/23750 _ The in vitro evaluation of compositions of the present invention can be accomplished using a variety of skin diffusion cell experimental protocols.
(See, for example, "Transdermal Drug Delivery" Ed. Jonathan Hadgraft et al., Chapter 9, Marcel Dekker Inc., New York; Bronaugh et al., f Phar. Sci., 75:1094-1097, (1986);
and S Bronaugh et al., J. Phar. Sci., 74: 64-67, (1985)). In general in vitro transdermal delivery experiments are conducted on either vertically or horizontally arranged diffusion cells. It is desirable to control various environmental factors that cah effect the rate of diffusion.
The factors include, for instance, temperature. This is because the rate of diffusion will increase with increasing temperature. Thus, it is important to consider various factors related to the skin surface including, skin surface coverings, microorganisms, vehicle formulation and duration of contact with the skin.
The transdermal delivery experiments are conducted by applying a finite amount of drug formulation onto the skin sample. The skin is placed on top of a flow-through permeation cell. Once the candidate molecule has penetrated through the stratum corneum, it will be transported it its proposed site of action. Typically, for in vitro experiments, the body mass is represented by physiological saline. The diffusion cell contains a receptor compartment, and typically the compartment is made as small as possible. After the molecule has penetrated the skin it is collected for assay. The most widely used assay procedure for studying transdermal delivery is radioactive labeling.
There exist a number of methods for identifying the distribution of the penetrant within the skin during the course of penetrations. These include, for example, tape stripping, autoradiographs, and skin sectioning. Using the flow-through permeation cell experiments describe above, the in vitro evaluation of formulations of the present invention can be accomplished by a person skilled in the art.
In addition to in vitro evaluation, in vivo evaluations of the formulations of the present invention have also been conducted. In these evaluations, New Zealand white albino rabbits are used. Each animal receives 100 mg/cm~ of the test material twice a day for five consecutive days. Six to eight hours following the first dose of the day, a second dose is administered on the same site to each rabbit. The test material is applied to the skin undiluted.
Each site is then scored for evidence of erythema and edema at 24, 48 and 72 hours following the final application. A mean primary irritation score (MPI) for each test animal is calculated as follows. For each observation period, the average erythema WO 99/24041 PCT/US98/23750 _ scores were calculated by dividing the sum erythema scores for all animals.
The edema scores were calculated in the same manner. The sum of the average erythema and edema scores is divided by the total number of observation periods to obtain the MPI
scores.
The following examples are offered for purposes of illustration. They are S intended neither to define nor to limit this invention in any manner.
EXAMPLES
x le 1 The following example illustrates a comparison between formulations 10 using oleic acid versus oleyl alcohol as a membrane fluidizer.
Testosterone formulations, in which either oleic acid or oleyl alcohol was used as the membrane fluidizer, were tested in vitro, demonstrating equivalent levels of drug delivery. The testosterone formulations were tested and the results indicated that the formulations containing oleyl alcohol produced much higher levels of skin irritation than did the testosterone formulations containing oleic acid. These tests indicate that substituting oleic acid as the membrane fluidizer in the PES not only maintains the system's ability to enhance topical and transdermal drug delivery, but produces the unanticipated result of reduced skin irritation.
Table I lists the formulations tested, identifying each one by its ingredients followed by the weight percent of each. Average testosterone flux and total erythema score followed by standard deviations are given for each formulation. The abbreviations used in the table are as follows:
T testosterone PG propylene glycol ET ethyl alcohol IPA isopropyl alcohol KH Klucel HF (hydroxypropylcellulose: gelling agent) O Acd oleic acid O Alc oleyl alcohol C1 Carbopol 1342 TEA Triethanolamine SD Standard deviation FormulationFormulation Average TestosteroneTotal Erythema Components flux, t SD Score After 120 h, t SD
A T2, PG37, ET15,21.21 f 1.87 4.0 t 0.3 IPA 15, KH
1, O Acd 1.0 B T2, PG37, ET15,15.08 t 3.96 8.7 t 0.3 IPA15, KFiI, O Alc 1.0 Table 2 illustrates a comparison between formulations using oleic acid versus oleyl alcohol. Similar to the comparison in Table I, formulations containing oleyl alcohol produced much higher levels of skin irritation than did the testosterone formulations containing oleic acid. These tests indicate that substituting oleic acid in the PES not only maintains the system's ability to enhance topical and transdermal drug delivery but produces the unanticipated result of reduced skin irritation.
FormulaActiveGlycolAlcoholAlcoholMbr GellingCrosslnkWater #I #2 Fluid 545 T PG ET I5.0IPA OAcd C 1 TEA 29.4 2.0 36.6 15.0 1.0 0.6 0.4 546 T PG ET 15.0IPA OAIc Cl TEA 29.4 2.0 36.6 15.0 1.0 0.6 0.4 In this experiment, the 545 formula had a cumulative flux of 22.63 and an irntation score of 5.0, whereas the 546 formula had a cumulative flux of 18.86 and an irritation score of 9.3.
SUBSTITUTE SHEET (RULE 26) ' ~ WO 99/24041 PCT1US98/23750 _.
c le 2 The following example illustrates preferred compositions for gel products of the present invention.
Ingredient R_ anee Ethanol 0.1 to 50% _ .
Propylene Glycol 0.1 to 50%
Isopropyl Alcohol 0.1 to 50%
Oleic Acid 0.1 to 50%
Gelling Agent 0.01 to 50%
Additional Irritation 0.1 to SO%
Reducers Preservatives 0 (the formulation may be self preserving) to 0.1 /a Dig 0% to saturation ,L~
The following example illustrates the preferred compositions for ointment products of the present invention:
In egg dient R~
Propylene Glycol 0.1 to 50%
Butylene Glycol 0.1 to SO%
Isopropyl Myristate 0.1 to 50%
Oleic Acid 0.1 to 50%
Mygliol 0.1 to 50%
Petrolatum 0.1 to 80%
Polawax 0.1 to 20%
Gelling Agent 0.01 to 50%
Additional Irritation Reducers0.1 to 50%
Preservatives 0 (formulation may be self preserving) to 0.1%
Dmg 0% to saturation Example 4 The following example illustrates preferred compositions for emulsion products of the present invention.
SUBSTITUTE SHEET (RULE 26) WO 99/24041 PCTNS98/23750 _ In egr dient Range Deionized Water 10 to 50%
Propylene Glycol 0.1 to 50%
Butylene Glycol 0.1 to 50%
Isopropyl Myristate 0.1 to 30%
Oleic Acid 0.1 to 20%
Cetyl Alcohol 0.1 to 5%
Mygliol 0.1 to 30%
Petrolatum 0.1 to 80%
Gelling 0.1 to 30%
Polawax 0.1 to 10%
Additional Irritation Reducers0.1 to 50%
Preservatives 0 (formulation may be self preserving) to 0.1%
Dig 0% to saturation ~x~amnlg 5 This example illustrates formulations in terms of ingredients and the weight percent of each ingredient.
ET IPA PG O Acd T IR IR CarbTEA Water No.
J 15.015.0 35.61.0 2.0 1.0--- 0.6 0.4 29.4 K 15.015.0 35.12.5 2.0 ------- 0.6 0.4 29.4 L 15.015.0 34.61.0 2.0 1.01.0 0.6 0.4 29.4 Examvlg_6 This example illustrates formulations in terms of ingredients and the weight percent of each ingredient.
SUBSTITUTE SHEET (RULE 26) Formulation DAA-97-602 DAA-97-601 DAA-97-600 No.
Ethanol 15.0 15.0 15.0 Isopropyl Alcohol15.0 15.0 15.0 Propylene glycol35.6 35.1 - 34.6 Oleic Acid 1.0 2.5 2.0 Testosterone 2.0 2.0 2.0 Irritation Reducing1.0 -- 1.0 Agent No. 1 Irritation Reducing-- -- 1.0 Agent No. 2 CARBOPOL 1342 0.6 0.6 0.6 Triethanolamine0.4 0.4 0.4 Water 29.4 29.4 29.4 With reference to Figure 1, the cumulative testosterone levels in a receiver reservoir delivered from the three topical formulations are compared to a commercial patch gel across excised pig skin. Formulation No. DAA-97-602 is represented by triangles, Formulation No. DAA-97-601 by diamonds, and Formulation No. DAA-97-is represented by squares. The circles represent the commercial patch gel.
Similar delivery profiles of these three formulations were seen using surgically removed human skin in the same skin delivery studies. Therefore, these formulations will have utility in people and other mammals suffering with systemic testosterone deficient disorders. Furthermore, these formulations can be used to deliver testosterone locally, and thus can be used in conditions where increase in local testosterone concentration is beneficial. An example of this kind of disorder is vulval lichen scelerosus.
The testosterone formulations described in this invention exhibited significantly lower levels of irritation than other marketed testosterone products, making them more acceptable to patients and thus improving compliance. These irritation studies measured both erythema (skin redness) and edema (skin swelling) development that are two hallmark features of skin inflammation. Both reactions could be primary SUBSTITUTE SHEET (RULE 26) clinical manifestations of skin inflammation, and may also be a prelude to even more severe conditions such as blister formation, necrosis, etc. While the combination of oleic acid and Carbopol 1342 produced very low irntating formulations, the incorporation of other irritation reducing agents can further decrease irritation. These anti-irritation 5 approaches can thus be used in combination in testosterone-delivering formulations, or any other topical product or dosage form. Thus, they have utility in minimizing irritation for all pharmaceutical; cosmeceutical or general skin care formulations.
10 Using a computer model, this example optimizes the '601 formulation by adjusting (1) testosterone concentration and (2) pH.
Statistical design: In this example, the pH range was set from 3 to 6, and testosterone concentration range was set from 0.5% to 2.0%. With these two definitions, the statistical software Echip ran through 16 unique formulations in order to identify the 15 optimal pH and concentration for testosterone delivery.
FnRiytilT.ATION CO POSITIONS:
ingredient 0.50% 1.00% ~~ 1.25%1.50% 2.00%
~
Forth. Form.~~#11:Forth. Forth. Forth.
#1: 5.0 #3: #7: #4: 8.0 8.0 Form. 8.0 3.0 Form.
Form. #8: #5: 3.0 #Z: 3.0 Form.
4.5 Forth. #9: 4.0 Form. #14: Form.
#8:3.0 8.0 #10:
Forth. 5.0 15: Form.
7.0 #12:
Form. 7.0 16: Form.
8.0 #13:
8.0 Testosterone 0.50 1.00 1.25 1.50 2.00 USPINF
Carbomer 1342 0.60 0.80 0.80 0.60 0.60 USP
Propylene Glycol35.81 35.44 35.33 35.23 35.05 USP
Isopropyl Alcohd15.24 15.18 15.12 15.08 15.00 USP
Dehydrated 15.24 15.16 15.12 15.08 15.00 alcohol USP
Oleic acid 2.50 2.50 2.50 2.50 2.50 USP
Trlethanolamineqs to Qs to qs to qs to qs to 99% pH pH pH pH pH
NF or HCI 1N
Butylated 0.050 0.050 0.050 0.050 0.050 Hydroxytoluene, NF
Purified water,29.87 29.72 29.64 29.54 29.40 USP
Since the 16 formulations (22 runs) could not be all tested on skin from a single donor; instead four separate studies were conducted. Study #5 was added to SUBSTITUTE SHEET (RULE 26) further investigate differences between pH 5 and 6. In each study, skin from a single donor was used and n=5-6 replicates were used for each formulation.
In this experiment, fresh human skin was obtained from local cosmetic surgeons, dermatomed within 24 hours at a thickness of 500 pm, and stored frozen at -80°C (1 week to 8 months). Before each experiment, the skin-was thawed at 4°C for about I6 hours, at room temperature for about 1 hour and mounted in I-cm2 flow-through diffusion cells. Flow rate was set to 3 ml/hr, and receptor phase was saline at 32°C. All cells were non-occluded and I O mg of formulation was applied at time 0 (dose = 10 mglcm2). In each study, all formulations were spiked with '4C-testosterone (~2 000 or 20,000 DPM per 10 mg dose). Both flux (6 time points, every 4 hours for 24 hours, analysis: HPLC) and skin content data were obtained (an alcoholic swab of the surface, 2 tape-strips, and the rest of the skin sample digested in NaOH, analysis:
scintillation counting).
RESULTS:
The results indicated that formulations having a pH from about 5 to about 6 gave the optimum formulations.
Amount ResiduekinResidue Amount on on skin in s skin FormulationsStudy testosterone- alcoholic - tape (uglg # swab strips- tissue) -permeated (ug/cm2) (uglcmz) in 24 hours (uglcm2) code composition average averages.d.average averages.d.
s.d. s.d.
and pH
# 4 2.00% 1 24.31 3.98 55.4 15.918.7 11.2409.3 112.5 test., pH 6.0 (601 ) 2 31.36 6.09 59.8 22.319.6 6.6 257.3 71.4 3 22.76 4.02 57.2 20.215.0 7.2 267.1 63.7 4 46.96 14.1979.3 5.821.4 7.0 726.8 111.5 5 35.45 5.63 51.2' 13.4'29.9 6.3 439.0 159.4 * alcoholic swab taken after a dry swab None of the formulations delivered an amount of testosterone significantly higher than that delivered by 601 (2% testosterone, pH 6.0). However, there seemed to be a trend for formulations at pH 5.0 to be consistently better - although not significantly -than the corresponding formulation at pH 6Ø
SUBSTITUTE SHEET (RULE 26) The same conclusion is further illustrated quantitatively in the table below:
Enhancement ratios for all studies (1-5) were calculated with reference to 601 (i.e.
cumulative amount permeated at 24 hours for formulation X divided by cumulative amount permeated at 24 hours from 601). These ratios were calculated at different pHs for 2 concentrations of testosterone (without concentration correction) from data obtained with same skin donor (i. e. in the same study).
In the table below, flux and skin analysis data were used to project the required area for the delivery of 5 mg/day and the amount of residue left on and in the skin if 1 g/100 cm2 of gel was applied to such area.
In vitro Required Total a~muiative area amount permeatedfor the testosteroneResidue leftTestosterone delivery on skin left in in 24 hoursof 5 mg dosed after 24 dosed skin per day hours after 24 (uglanz. (swab +tape hours mean t strips) SD, n = (1g of 5-6) gel per 100crn=) 2.0% 47.0 14.2 108 cm2 21.2 mg 10.7 mg 2.8 mg gel pH 6.0 (form. (100%) (49 t 5 %) (13 t 4 %}
4) 1.O~o 28.0 t 4.8 178 cm= 17.8 mg 5.7 mg 2.5 mg gei pH 6.0 (100%) (32 t 4 h) (14 t 2 %) (form.
14) Example 9 Clinical Formulations of Testosterone Topical Gel - ~/O WOW
INGREDIENTS 1.0% 2.0%
Testosterone, USP/NF 1.00 2.00 Ethanol Deh drated USP 15.00 15.00 2-Pro anol, USP _ 15.00 15.00 Pro lene Gl col, USP 35.05 35.05 Oleic Acid, NF 2.50 2.50 Bu fated H drox oluene, NF 0.05 0.05 Carbomer, USP 0.60 0.60 Triethanolamine, NF .s. to H 0.30 - 0.40 0.30 - 0.40 6.0 Purified Water, USP .s. 30.00 - 29.90 29.00 - 28.90 Total 100.00 100.0 Gram/20-Kg Batch ~N'GREDIENTS 1.0% 2.0%
Testosterone, USP/NF 200.00 400.00 Ethanol, Deh drated' USP/NF 3000.00 3000.00 2-Pro anol, USP 3000.00 3000.00 Pro lene Gl col, USP 7010.00 7010.00 Oleic Acid NF 500.00 500.00 Bu fated H drox oluene, NF 10.00 10.00 Carbomer , USP 120.00 120.00 Triethanolamine , NF .s. 60.00 - 80.00 60.00 - 80.00 Purified Water , USP .s. 6000.00 - 5980.005800.00 - 5780.00 Total 20 000.00 20,000.00 Typical Manufacturing Procedure for the Clinical Formulations Procedure for the preparation of a typical batch of 1.0% or 2.0% testosterone topical get:
1) Charge 95% of purified water, USP to a suitable vessel and ad Carbomer, USP with mixing. Mix the slurry at 20-30°C until the Carbomer is completely dispersed and hydrated.
2) Add dehydrated ethanol, USP, 2-propanol, USP, oleic acid, butylated hydroxytoluene, NF, testosterone, USP/NF and propylene glycol, USP to the primary compounding vessel. After each addition, the mixture is stirred to complete dissolution.
3) Add the entire amount of Carbomer gel to the coinpounding-vessel with good stirring. Add triethanolamine, NF slowly with mixing to thicken the gel.
4) Check the pH and adjust the pH to target using extra triethanolamine, NF or 1.0 N HCI, USP, if necessary. Then q.s. to the final weight with purified water, USP.
5) Samples are taken from top, middle and bottom of the compounding vessel for in-process assays for testosterone, ethanol and pH.
6) Fill the bulk gel into containers/bottles.
Although the invention has been described with reference to prefer ed embodiments and examples thereof, the scope of the present invention is not limited only to those described embodiments. As will be apparent to persons skilled in the art, modifications and adaptations to the above-described invention can be made without departing from the spirit and scope of the invention, which is defined and circumscribed by the appended claims.
In certain aspects, the present invention relates to transdermal and topical drug delivery. In particular, using this mode of drug delivery, enhancement of the penetration of topically applied drugs is typically accompanied by an increase in skin irntation. As such, in one aspect, the present invention relates~to a composition for topical application having penetration-enhancing properties, the composition comprising:
a) an active agent; b) a penetration-enhancing system comprising: (i) a membrane Iluidizer; (ii) a C1-Ca alcohol; and (iii) a glycol. In certain embodiments, the composition further comprises (iv) a gelling agent. This penetration enhancing system of the present invention increases transdermal and topical drug delivery while decreasing skin irritation, thereby allowing high levels of drug delivery to be achieved without causing unacceptable adverse skin reactions.
The active ingredients of the present invention can include all types of therapeutic drugs or other compounds. The active ingredients include both systemically active agents as well as topically active agents. Systemically active agents induce a biological response upon entering the blood stream. Topically active agents refer to compounds that induce a biologic response in the skin or mucous membrane.
Systemically active agents include, but are not limited to, anti-infectives such as antibiotics and antiviral agents, analgesics and analgesic combinations, anorexics and appetite suppressants, anthelmintics, anesthetics, antiarthritics, antiasthma agents, anticonvulsants, antidepressants, antidiabetic agents, antidiarrheals, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness agents, antinauseants, antineoplastics, antiparkinsonism agents, antipruritics, antipsychotics, antipyretics, antispasmodics, anticholinergics, sympathomimetics, xanthine derivatives, cardiovascular preparations including calcium channel blockers, beta Mockers, antiarrhythmics, antihypertensives, diuretics, vasodilators (general, coronary, peripheral and cerebral), central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, hormones, hypnotics, immunosuppressives, muscle relaxants, parasympatholytics, parasympathomimetics, psychostimulants, sedatives, tranquilizers, antioxidants, vitamins, minerals, other nutrients, and herbal extracts or preparations.
Topically active agents include, but are not limited to, anti-inflammatory agents, anti-infectives, analgesics, anesthetics, antihistamines, photoprotective agents, antineoplastics, antipruritics, neuropeptides, channel blockers, hydrocarbon compositions, hormones, vitamins, minerals, antioxidants, other nutrients, herbal extracts or preparations, and cosmetic ingredients. Certain agents listed above are active both systemically and in the skin and mucous membrane.
The amount of systemically and/or topically active agent included in the 5 formulation is subject to the degree to which penetration enhancement is achieved. When the increase in penetration is relatively large, lesser amounts of the active agent can be used. With these considerations, the appropriate amounts or concentrations in any given instance will be readily apparent to the skilled physician prescribing the formulation or to the formulator preparing the formulation for use by the lay person.
In a preferred embodiment, the active agent is a mammalian sex hormone, hormone derivative, or hormone mimetic. Examples include, but are not limited testosterone or estradiol. The active ingredient is present in the composition in about 0.1 to about 10 % weight to weight: Preferably, from about 0.1% to about S %, and more preferably, from about 1 % to about 2 % weight to weight of the composition.
The compositions of the present invention include oleic acid. Oleic acid (cis-9-octadecenoic acid) is a monounsaturated fatty acid. Oleic acid is present from about O.I % to about 10 % weight to weight of the composition, preferably it is present from about 0.1 % to about 5 % weight to weight of the composition. The ability of oleic acid to lessen the irritation caused by other penetration enhancing agents and/or other formulation components to a greater extent than oleyl alcohol has not been described previously. By adding oleic acid to the compositions of the present invention, such as testosterone formulations, the skin irritation caused by these formulations is markedly reduced. Surprisingly, the combination of oleic acid with a gelling agent, such as CARBOPOL~ (a polyacrylic acid), and/or other irritation reducing agents results in formulations that produce unexpectedly low levels of skin irritation.
Before the advent of the present invention, it was believed that oleic acid, oleyl alcohol and esters of oleic acid were all equal in their ability to enhance penetration and reduce skin irritation. Surprisingly, it has now been discovered that oleic acid is far superior to oleyl alcohol in its ability to reduce skin irritation. This is especially true when oleic acid is used in combination with a gelling agent.
In addition to oleic acid, the penetrating enhancing system of the present invention contains an alcohol. As used herein the term "alcohol" refers to a monohydric alcohol, preferably an aliphatic alcohol and more preferably a saturated monohydric aliphatic alcohol. Examples are methanol, ethanol, propanol, isopropanol, and octanol.
In the present invention, a Ci-C4 alcohol is preferred. These include, but are not limited to, ethanol, propanol, isopropanol and mixtures thereof. Mixtures include, for example, ethanol and isopropanol.
The compositions in accordance with the present invention contain an alcohol in about 5 % to about 55 % weight to weight of the composition.
Preferably, the alcohol is present from about 10 % to about 40 % weight to weight and more preferably, from about 25 % to about 35 % weight to weight of the composition.
In addition to oleic acid and an alcohol, the penetration-enhancing system of the present invention comprises a glycol. As used herein, the term "glycol"
refers to a polyhydric alcohol, preferably a dihydric alcohol. Examples are ethylene glycol, propylene glycol, butylene glycol and glycerol. Preferably, the glycol is ethylene glycol, propylene glycol, butylene glycol and mixtures thereof.
The compositions of the present invention contain a glycol in about 25 to about 55 % weight to weight of the composition. Preferably, the glycol content is from about 30 % to about 40 % weight to weight of the composition.
In addition, the compositions of the present invention optionally comprise a gelling agent. Formulations with a gelling agent in conjunction with oleic acid were tested. Formulations containing a gelling agent, for instance, CARBOPOL# 1342 (a polyacrylic acid), produced lower levels of skin irritation than did formulations containing no Gelling agent. These tests indicate that including a gelling agent in the PES
maintains the system's ability to enhance topical and transdermal drug delivery, while reducing irritation associated with topical or transdermai application. This finding is quite remarkable because the inclusion of lower alcohols is known to induce skin sensitization and was heretofore believed to be unsuitable as solvents for compounds applied to the skin. Surprisingly, including a gelling agent with oleic acid resulted in lower irritation levels than formulations with oleyl alcohol and a Gelling agent.
Suitable gelling agents of the present invention include, but are not limited to, Carbopol'1342, Carbopo1~940, Klucel~and Klucel HF. Synonyms for carbopol are carbomer, poly(1-carboxyethylene) or poly(acrylic acid). Those of skill in the art will know of other eeIIinG agents that are suitable to practice the present invention. The gelling went is present from about 1 % to about 10 % weight to weight of the 'Trade-mark composition. Preferably, the gelling agent is present from about 1 % to about 5 %, and more preferably, from about 1 % to about 3 % weight to weight of the composition.
The formulations in which the compositions of the present invention are incorporated in can assume any of a variety of dosage forms. Examples are creams, lotions, gels, ointments, suppositories, sprays, aerosols, buccal and sublingual tablets and various passive and active transdermal devices for absorption through the skin and mucous membranes.
The penetration enhancing compositions of this invention may constitute a small amount of the formulation or a large amount depending on which excipient composition is used, which systemically and/or topically active agent is used and the type of biological effect sought. The amount will be readily apparent to those skilled in the art, since the total amount of penetration enhancers will be approximately the same as those of the prior art. For example, when the potency of the penetration enhancement composition is greatly increased, lower quantities can be used.
In addition to the foregoing composition components, the compositions of the present invention can optionally contain other ingredients. For example, triethanolamine, can be added as a crosslinking agent. A preservative, such as betahydoxytoluene can be added. Other irritation reducing agents can be added.
In this regard, irritation reducing agents include, but are not limited to, glycerol.
In some instances, semi-solid testosterone formulations have been prepared with propylene glycol and/or butylene glycol as the glycol component, ethyl alcohol and/or isopropyl alcohol as the alcohol component. Preservatives, a cross-linking agent, and additional irritation reducing agents have been included in formulations prepared in accordance with this invention.
Various conditions and disorders are treatable, prevented, or promoted by the compositions of the present invention. Examples of conditions include, but are not limited to, treatment of conditions related to testosterone deficiency;
treatment of balanitis xerotic obliterans; treatment of lichen sclerosis et atrophicus; treatment of menopausal and postmenopausal symptoms and signs; prevention and/or reduction of aging related changes to skin and mucous membranes; prevention and/or reduction of skin pigmentation; prevention and/or reduction of skin roughness, wrinkles, furrows, fragility and/or atrophy; prevention and/or reduction of nail thinning and/or fracturing; prevention and/or reduction of hair thinning and/or fracturing; prevention and/or reduction of neoplasia of the skin, mucous membranes, other epithelia, and glands;
prevention and/or reduction of age-related bone demineralization; promotion of hair and/or nail growth;
promotion of increased muscle size and stamina; peversal of muscle wasting;
promotion of increased speed of reaction time and reversal of decreased reaction time;
promotion of increased growth of appendages and organism as a whole; prevention and/or reversal of xerosis; promotion of healing or as treatment for hemorrhoids or anal fissures.
As such, in another aspect, the present invention relates to a method for administering a topically or systemically active agent, the method comprising:
topically administering to a mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a C1-C4 alcohol;
and (iii) a glycol. In some embodiments, the penetration-enhancing system further comprises (iv) a gelling agent. In certain preferred embodiments, the method relates to treatment of conditions related to testosterone deficiency.
In yet another aspect, the present invention relates to a method of reducing inflammation associated with topical application of an active agent, the method comprising: topically administering to a mammal a composition comprising: a) an active agent; and b) a penetration-enhancing system comprising: (i) oleic acid; (ii) a C~-Ca alcohol; and (iii) a glycol. In some embodiments, the penetration-enhancing system further comprises (iv) a gelling agent.
Subjects to whom the formulations can be administered are primarily mammals, including humans, pets, and livestock and other farm animals. The invention is of greatest interest in its application to humans. The term "topical administration" or "topical application" refers to directly layering or spreading upon epidermal tissue, especially outer skin or membrane, including the skin or membrane of the oral or vaginal cavities.
The site of application is dependent on many factors including, but not limited to, the amount of drug to be delivered, the extent of enhancement required, the irritation response manifested and the time of application. Thus, another important facet of this invention is the use of these compositions with drugs other than for example, testosterone, or to apply such formulations, or topical products in general, specifically to the soles of the feet, the palms of the hands or other immune-privileged sites of the body.
Also, the drugs, compositions or products may be administered later in the day or at night when the permeability at the site of application is higher.
WO 99/24041 PCT/US98/23750 _ The in vitro evaluation of compositions of the present invention can be accomplished using a variety of skin diffusion cell experimental protocols.
(See, for example, "Transdermal Drug Delivery" Ed. Jonathan Hadgraft et al., Chapter 9, Marcel Dekker Inc., New York; Bronaugh et al., f Phar. Sci., 75:1094-1097, (1986);
and S Bronaugh et al., J. Phar. Sci., 74: 64-67, (1985)). In general in vitro transdermal delivery experiments are conducted on either vertically or horizontally arranged diffusion cells. It is desirable to control various environmental factors that cah effect the rate of diffusion.
The factors include, for instance, temperature. This is because the rate of diffusion will increase with increasing temperature. Thus, it is important to consider various factors related to the skin surface including, skin surface coverings, microorganisms, vehicle formulation and duration of contact with the skin.
The transdermal delivery experiments are conducted by applying a finite amount of drug formulation onto the skin sample. The skin is placed on top of a flow-through permeation cell. Once the candidate molecule has penetrated through the stratum corneum, it will be transported it its proposed site of action. Typically, for in vitro experiments, the body mass is represented by physiological saline. The diffusion cell contains a receptor compartment, and typically the compartment is made as small as possible. After the molecule has penetrated the skin it is collected for assay. The most widely used assay procedure for studying transdermal delivery is radioactive labeling.
There exist a number of methods for identifying the distribution of the penetrant within the skin during the course of penetrations. These include, for example, tape stripping, autoradiographs, and skin sectioning. Using the flow-through permeation cell experiments describe above, the in vitro evaluation of formulations of the present invention can be accomplished by a person skilled in the art.
In addition to in vitro evaluation, in vivo evaluations of the formulations of the present invention have also been conducted. In these evaluations, New Zealand white albino rabbits are used. Each animal receives 100 mg/cm~ of the test material twice a day for five consecutive days. Six to eight hours following the first dose of the day, a second dose is administered on the same site to each rabbit. The test material is applied to the skin undiluted.
Each site is then scored for evidence of erythema and edema at 24, 48 and 72 hours following the final application. A mean primary irritation score (MPI) for each test animal is calculated as follows. For each observation period, the average erythema WO 99/24041 PCT/US98/23750 _ scores were calculated by dividing the sum erythema scores for all animals.
The edema scores were calculated in the same manner. The sum of the average erythema and edema scores is divided by the total number of observation periods to obtain the MPI
scores.
The following examples are offered for purposes of illustration. They are S intended neither to define nor to limit this invention in any manner.
EXAMPLES
x le 1 The following example illustrates a comparison between formulations 10 using oleic acid versus oleyl alcohol as a membrane fluidizer.
Testosterone formulations, in which either oleic acid or oleyl alcohol was used as the membrane fluidizer, were tested in vitro, demonstrating equivalent levels of drug delivery. The testosterone formulations were tested and the results indicated that the formulations containing oleyl alcohol produced much higher levels of skin irritation than did the testosterone formulations containing oleic acid. These tests indicate that substituting oleic acid as the membrane fluidizer in the PES not only maintains the system's ability to enhance topical and transdermal drug delivery, but produces the unanticipated result of reduced skin irritation.
Table I lists the formulations tested, identifying each one by its ingredients followed by the weight percent of each. Average testosterone flux and total erythema score followed by standard deviations are given for each formulation. The abbreviations used in the table are as follows:
T testosterone PG propylene glycol ET ethyl alcohol IPA isopropyl alcohol KH Klucel HF (hydroxypropylcellulose: gelling agent) O Acd oleic acid O Alc oleyl alcohol C1 Carbopol 1342 TEA Triethanolamine SD Standard deviation FormulationFormulation Average TestosteroneTotal Erythema Components flux, t SD Score After 120 h, t SD
A T2, PG37, ET15,21.21 f 1.87 4.0 t 0.3 IPA 15, KH
1, O Acd 1.0 B T2, PG37, ET15,15.08 t 3.96 8.7 t 0.3 IPA15, KFiI, O Alc 1.0 Table 2 illustrates a comparison between formulations using oleic acid versus oleyl alcohol. Similar to the comparison in Table I, formulations containing oleyl alcohol produced much higher levels of skin irritation than did the testosterone formulations containing oleic acid. These tests indicate that substituting oleic acid in the PES not only maintains the system's ability to enhance topical and transdermal drug delivery but produces the unanticipated result of reduced skin irritation.
FormulaActiveGlycolAlcoholAlcoholMbr GellingCrosslnkWater #I #2 Fluid 545 T PG ET I5.0IPA OAcd C 1 TEA 29.4 2.0 36.6 15.0 1.0 0.6 0.4 546 T PG ET 15.0IPA OAIc Cl TEA 29.4 2.0 36.6 15.0 1.0 0.6 0.4 In this experiment, the 545 formula had a cumulative flux of 22.63 and an irntation score of 5.0, whereas the 546 formula had a cumulative flux of 18.86 and an irritation score of 9.3.
SUBSTITUTE SHEET (RULE 26) ' ~ WO 99/24041 PCT1US98/23750 _.
c le 2 The following example illustrates preferred compositions for gel products of the present invention.
Ingredient R_ anee Ethanol 0.1 to 50% _ .
Propylene Glycol 0.1 to 50%
Isopropyl Alcohol 0.1 to 50%
Oleic Acid 0.1 to 50%
Gelling Agent 0.01 to 50%
Additional Irritation 0.1 to SO%
Reducers Preservatives 0 (the formulation may be self preserving) to 0.1 /a Dig 0% to saturation ,L~
The following example illustrates the preferred compositions for ointment products of the present invention:
In egg dient R~
Propylene Glycol 0.1 to 50%
Butylene Glycol 0.1 to SO%
Isopropyl Myristate 0.1 to 50%
Oleic Acid 0.1 to 50%
Mygliol 0.1 to 50%
Petrolatum 0.1 to 80%
Polawax 0.1 to 20%
Gelling Agent 0.01 to 50%
Additional Irritation Reducers0.1 to 50%
Preservatives 0 (formulation may be self preserving) to 0.1%
Dmg 0% to saturation Example 4 The following example illustrates preferred compositions for emulsion products of the present invention.
SUBSTITUTE SHEET (RULE 26) WO 99/24041 PCTNS98/23750 _ In egr dient Range Deionized Water 10 to 50%
Propylene Glycol 0.1 to 50%
Butylene Glycol 0.1 to 50%
Isopropyl Myristate 0.1 to 30%
Oleic Acid 0.1 to 20%
Cetyl Alcohol 0.1 to 5%
Mygliol 0.1 to 30%
Petrolatum 0.1 to 80%
Gelling 0.1 to 30%
Polawax 0.1 to 10%
Additional Irritation Reducers0.1 to 50%
Preservatives 0 (formulation may be self preserving) to 0.1%
Dig 0% to saturation ~x~amnlg 5 This example illustrates formulations in terms of ingredients and the weight percent of each ingredient.
ET IPA PG O Acd T IR IR CarbTEA Water No.
J 15.015.0 35.61.0 2.0 1.0--- 0.6 0.4 29.4 K 15.015.0 35.12.5 2.0 ------- 0.6 0.4 29.4 L 15.015.0 34.61.0 2.0 1.01.0 0.6 0.4 29.4 Examvlg_6 This example illustrates formulations in terms of ingredients and the weight percent of each ingredient.
SUBSTITUTE SHEET (RULE 26) Formulation DAA-97-602 DAA-97-601 DAA-97-600 No.
Ethanol 15.0 15.0 15.0 Isopropyl Alcohol15.0 15.0 15.0 Propylene glycol35.6 35.1 - 34.6 Oleic Acid 1.0 2.5 2.0 Testosterone 2.0 2.0 2.0 Irritation Reducing1.0 -- 1.0 Agent No. 1 Irritation Reducing-- -- 1.0 Agent No. 2 CARBOPOL 1342 0.6 0.6 0.6 Triethanolamine0.4 0.4 0.4 Water 29.4 29.4 29.4 With reference to Figure 1, the cumulative testosterone levels in a receiver reservoir delivered from the three topical formulations are compared to a commercial patch gel across excised pig skin. Formulation No. DAA-97-602 is represented by triangles, Formulation No. DAA-97-601 by diamonds, and Formulation No. DAA-97-is represented by squares. The circles represent the commercial patch gel.
Similar delivery profiles of these three formulations were seen using surgically removed human skin in the same skin delivery studies. Therefore, these formulations will have utility in people and other mammals suffering with systemic testosterone deficient disorders. Furthermore, these formulations can be used to deliver testosterone locally, and thus can be used in conditions where increase in local testosterone concentration is beneficial. An example of this kind of disorder is vulval lichen scelerosus.
The testosterone formulations described in this invention exhibited significantly lower levels of irritation than other marketed testosterone products, making them more acceptable to patients and thus improving compliance. These irritation studies measured both erythema (skin redness) and edema (skin swelling) development that are two hallmark features of skin inflammation. Both reactions could be primary SUBSTITUTE SHEET (RULE 26) clinical manifestations of skin inflammation, and may also be a prelude to even more severe conditions such as blister formation, necrosis, etc. While the combination of oleic acid and Carbopol 1342 produced very low irntating formulations, the incorporation of other irritation reducing agents can further decrease irritation. These anti-irritation 5 approaches can thus be used in combination in testosterone-delivering formulations, or any other topical product or dosage form. Thus, they have utility in minimizing irritation for all pharmaceutical; cosmeceutical or general skin care formulations.
10 Using a computer model, this example optimizes the '601 formulation by adjusting (1) testosterone concentration and (2) pH.
Statistical design: In this example, the pH range was set from 3 to 6, and testosterone concentration range was set from 0.5% to 2.0%. With these two definitions, the statistical software Echip ran through 16 unique formulations in order to identify the 15 optimal pH and concentration for testosterone delivery.
FnRiytilT.ATION CO POSITIONS:
ingredient 0.50% 1.00% ~~ 1.25%1.50% 2.00%
~
Forth. Form.~~#11:Forth. Forth. Forth.
#1: 5.0 #3: #7: #4: 8.0 8.0 Form. 8.0 3.0 Form.
Form. #8: #5: 3.0 #Z: 3.0 Form.
4.5 Forth. #9: 4.0 Form. #14: Form.
#8:3.0 8.0 #10:
Forth. 5.0 15: Form.
7.0 #12:
Form. 7.0 16: Form.
8.0 #13:
8.0 Testosterone 0.50 1.00 1.25 1.50 2.00 USPINF
Carbomer 1342 0.60 0.80 0.80 0.60 0.60 USP
Propylene Glycol35.81 35.44 35.33 35.23 35.05 USP
Isopropyl Alcohd15.24 15.18 15.12 15.08 15.00 USP
Dehydrated 15.24 15.16 15.12 15.08 15.00 alcohol USP
Oleic acid 2.50 2.50 2.50 2.50 2.50 USP
Trlethanolamineqs to Qs to qs to qs to qs to 99% pH pH pH pH pH
NF or HCI 1N
Butylated 0.050 0.050 0.050 0.050 0.050 Hydroxytoluene, NF
Purified water,29.87 29.72 29.64 29.54 29.40 USP
Since the 16 formulations (22 runs) could not be all tested on skin from a single donor; instead four separate studies were conducted. Study #5 was added to SUBSTITUTE SHEET (RULE 26) further investigate differences between pH 5 and 6. In each study, skin from a single donor was used and n=5-6 replicates were used for each formulation.
In this experiment, fresh human skin was obtained from local cosmetic surgeons, dermatomed within 24 hours at a thickness of 500 pm, and stored frozen at -80°C (1 week to 8 months). Before each experiment, the skin-was thawed at 4°C for about I6 hours, at room temperature for about 1 hour and mounted in I-cm2 flow-through diffusion cells. Flow rate was set to 3 ml/hr, and receptor phase was saline at 32°C. All cells were non-occluded and I O mg of formulation was applied at time 0 (dose = 10 mglcm2). In each study, all formulations were spiked with '4C-testosterone (~2 000 or 20,000 DPM per 10 mg dose). Both flux (6 time points, every 4 hours for 24 hours, analysis: HPLC) and skin content data were obtained (an alcoholic swab of the surface, 2 tape-strips, and the rest of the skin sample digested in NaOH, analysis:
scintillation counting).
RESULTS:
The results indicated that formulations having a pH from about 5 to about 6 gave the optimum formulations.
Amount ResiduekinResidue Amount on on skin in s skin FormulationsStudy testosterone- alcoholic - tape (uglg # swab strips- tissue) -permeated (ug/cm2) (uglcmz) in 24 hours (uglcm2) code composition average averages.d.average averages.d.
s.d. s.d.
and pH
# 4 2.00% 1 24.31 3.98 55.4 15.918.7 11.2409.3 112.5 test., pH 6.0 (601 ) 2 31.36 6.09 59.8 22.319.6 6.6 257.3 71.4 3 22.76 4.02 57.2 20.215.0 7.2 267.1 63.7 4 46.96 14.1979.3 5.821.4 7.0 726.8 111.5 5 35.45 5.63 51.2' 13.4'29.9 6.3 439.0 159.4 * alcoholic swab taken after a dry swab None of the formulations delivered an amount of testosterone significantly higher than that delivered by 601 (2% testosterone, pH 6.0). However, there seemed to be a trend for formulations at pH 5.0 to be consistently better - although not significantly -than the corresponding formulation at pH 6Ø
SUBSTITUTE SHEET (RULE 26) The same conclusion is further illustrated quantitatively in the table below:
Enhancement ratios for all studies (1-5) were calculated with reference to 601 (i.e.
cumulative amount permeated at 24 hours for formulation X divided by cumulative amount permeated at 24 hours from 601). These ratios were calculated at different pHs for 2 concentrations of testosterone (without concentration correction) from data obtained with same skin donor (i. e. in the same study).
In the table below, flux and skin analysis data were used to project the required area for the delivery of 5 mg/day and the amount of residue left on and in the skin if 1 g/100 cm2 of gel was applied to such area.
In vitro Required Total a~muiative area amount permeatedfor the testosteroneResidue leftTestosterone delivery on skin left in in 24 hoursof 5 mg dosed after 24 dosed skin per day hours after 24 (uglanz. (swab +tape hours mean t strips) SD, n = (1g of 5-6) gel per 100crn=) 2.0% 47.0 14.2 108 cm2 21.2 mg 10.7 mg 2.8 mg gel pH 6.0 (form. (100%) (49 t 5 %) (13 t 4 %}
4) 1.O~o 28.0 t 4.8 178 cm= 17.8 mg 5.7 mg 2.5 mg gei pH 6.0 (100%) (32 t 4 h) (14 t 2 %) (form.
14) Example 9 Clinical Formulations of Testosterone Topical Gel - ~/O WOW
INGREDIENTS 1.0% 2.0%
Testosterone, USP/NF 1.00 2.00 Ethanol Deh drated USP 15.00 15.00 2-Pro anol, USP _ 15.00 15.00 Pro lene Gl col, USP 35.05 35.05 Oleic Acid, NF 2.50 2.50 Bu fated H drox oluene, NF 0.05 0.05 Carbomer, USP 0.60 0.60 Triethanolamine, NF .s. to H 0.30 - 0.40 0.30 - 0.40 6.0 Purified Water, USP .s. 30.00 - 29.90 29.00 - 28.90 Total 100.00 100.0 Gram/20-Kg Batch ~N'GREDIENTS 1.0% 2.0%
Testosterone, USP/NF 200.00 400.00 Ethanol, Deh drated' USP/NF 3000.00 3000.00 2-Pro anol, USP 3000.00 3000.00 Pro lene Gl col, USP 7010.00 7010.00 Oleic Acid NF 500.00 500.00 Bu fated H drox oluene, NF 10.00 10.00 Carbomer , USP 120.00 120.00 Triethanolamine , NF .s. 60.00 - 80.00 60.00 - 80.00 Purified Water , USP .s. 6000.00 - 5980.005800.00 - 5780.00 Total 20 000.00 20,000.00 Typical Manufacturing Procedure for the Clinical Formulations Procedure for the preparation of a typical batch of 1.0% or 2.0% testosterone topical get:
1) Charge 95% of purified water, USP to a suitable vessel and ad Carbomer, USP with mixing. Mix the slurry at 20-30°C until the Carbomer is completely dispersed and hydrated.
2) Add dehydrated ethanol, USP, 2-propanol, USP, oleic acid, butylated hydroxytoluene, NF, testosterone, USP/NF and propylene glycol, USP to the primary compounding vessel. After each addition, the mixture is stirred to complete dissolution.
3) Add the entire amount of Carbomer gel to the coinpounding-vessel with good stirring. Add triethanolamine, NF slowly with mixing to thicken the gel.
4) Check the pH and adjust the pH to target using extra triethanolamine, NF or 1.0 N HCI, USP, if necessary. Then q.s. to the final weight with purified water, USP.
5) Samples are taken from top, middle and bottom of the compounding vessel for in-process assays for testosterone, ethanol and pH.
6) Fill the bulk gel into containers/bottles.
Although the invention has been described with reference to prefer ed embodiments and examples thereof, the scope of the present invention is not limited only to those described embodiments. As will be apparent to persons skilled in the art, modifications and adaptations to the above-described invention can be made without departing from the spirit and scope of the invention, which is defined and circumscribed by the appended claims.
Claims (49)
1. A membrane fluidizer composition for use in preparation of a medicament for topical administration of an active agent which is a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof, said composition comprising:
(i) oleic acid;
(ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
(i) oleic acid;
(ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
2. The composition of claim 1, having a pH of about 3 to about 6.
3. The composition of claim 1, having a pH of about 5 to about 6.
4. A pharmaceutical composition for topical administration comprising:
(a) an active agent which is a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof; and (b) a penetration-enhancing system comprising:
(i) oleic acid;
(ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
(a) an active agent which is a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof; and (b) a penetration-enhancing system comprising:
(i) oleic acid;
(ii) at least one C1-C4 alcohol; and (iii) at least one glycol.
5. The composition of claim 4, having a pH of about 3 to about 6.
6. The composition of claim 4, having a pH of about 5 to about 6.
7. A composition in accordance with any one of claims 4-6, wherein said active agent is present from about 0.1% to about 10% weight to weight of said composition.
8. A composition in accordance with claim 7, wherein said active agent is present from about 0.1% to about 5% weight to weight of said composition.
9. A composition in accordance with claim 7, wherein said active agent is present from about 0.1% to about 2% weight to weight of said composition.
10. A composition in accordance with claim 7, wherein said active agent is present from about 0.5% to about 2% weight to weight of said composition.
11. A composition in accordance with claim 7, wherein said active agent is present from about 1% to about 2% weight to weight of said composition.
12. A composition in accordance with any one of claims 1-11, wherein said active agent is testosterone, a testosterone derivative, or a mixture thereof.
13. A composition in accordance with claim 12, wherein said active agent is selected from the group consisting of testosterone, testosterone propionate, and mixtures thereof.
14. A composition in accordance with claim 13, wherein said active agent is testosterone.
15. A composition in accordance with claim 13, wherein said active agent is testosterone propionate.
16. A composition in accordance with any one of claims 1-11, wherein said active agent is estradiol, an estradiol derivative, or a mixture thereof.
17. A composition in accordance with any one of claims 1-16, wherein said oleic acid is present from about 0.1% to about 10% weight to weight of said composition.
18. A composition in accordance with claim 17, wherein said oleic acid is present from about 0.1% to about 5% weight to weight of said composition.
19. A composition in accordance with any one of claims 1-18, wherein said at least one C1-C4 alcohol is selected from the group consisting of ethanol, propanol, isopropanol and mixtures thereof.
20. A composition in accordance with claim 19, wherein said at least one C1-C4 alcohol is ethanol.
21. A composition in accordance with claim 19, wherein said at least one C1-C4 alcohol is propanol.
22. A composition in accordance with claim 19, wherein said at least one C1-C4 alcohol is isopropanol.
23. A composition in accordance with claim 19, wherein said at least one C1-C4 alcohol is a mixture of ethanol and isopropanol.
24. A composition in accordance with any one of claims 1-18, wherein said at least one C1-C4 alcohol is a C3 alcohol.
25. A composition in accordance with any one of claims 1-24, wherein said at least one C1-C4 alcohol is present from about 5% to about 65% weight to weight of said composition.
26. A composition in accordance with claim 25, wherein said at least one C1-C4 alcohol is present from about 10% to about 40% weight to weight of said composition.
27. A composition in accordance with claim 25, wherein said at least one C1-C4 alcohol is present from about 25% to about 35% weight to weight of said composition.
28. A composition in accordance with any one of claims 1-27, wherein said at least one glycol is selected from the group consisting of ethylene glycol, propylene glycol, butylene glycol and mixtures thereof.
29. A composition in accordance with claim 28, wherein said at least one glycol is ethylene glycol.
30. A composition in accordance with claim 28, wherein said at least one glycol is butylene glycol.
31. A composition in accordance with claim 28, wherein said at least one glycol is propylene glycol.
32. A composition in accordance with claim 28, wherein said at least one glycol is a mixture of ethylene glycol and butylene glycol.
33. A composition in accordance with claim 28, wherein said at least one glycol is a mixture of propylene glycol and butylene glycol.
34. A composition in accordance with any one of claims 1-33, wherein said at least one glycol is present from about 25% to about 55% weight to weight of said composition.
35. A composition in accordance with claim 34, wherein said at least one glycol is present from about 30% to about 40% weight to weight of said composition.
36. A composition in accordance with any one of claims 1-35, further comprising a gelling agent.
37. The composition of claim 36, wherein the gelling agent is a carbomer, a poly(1-carboxylethylene), or a polyacrylic acid.
38. A composition in accordance with claim 36, wherein the gelling agent is selected from the group consisting of Carbopol.TM. 1342, Carbopol.TM. 940, Klucel.TM.
and Klucel.TM.
HF.
and Klucel.TM.
HF.
39. A composition in accordance with claim 38, wherein said gelling agent is Carbopol.TM. 1342.
40. A composition in accordance with any one of claims 36-39, wherein the gelling agent is present from about 0.1% to about 10% weight to weight of said composition.
41. A composition in accordance with claim 40, wherein said gelling agent is present from about 0.1% to about 5% weight to weight of said composition.
42. A composition in accordance with claim 40, wherein said gelling agent is present from about 1% to about 3% weight to weight of said composition.
43. A composition in accordance with any one of claims 1-42, further comprising an irritation reducing agent.
44. A composition in accordance with claim 43, wherein said irritation reducing agent is glycerol.
45. A composition in accordance with claim 43 or 44, wherein said irritation reducing agent is present from about 0.1% to about 15% weight to weight of said composition.
46. A composition in accordance with claim 45, wherein said irritation reducing agent is present from about 0.1% to about 5% weight to weight of said composition.
47. Use of the composition of any one of claims 1-46, for treatment of a patient who would benefit from administration of a hormone.
48. A method of making a pharmaceutical composition for topical administration, said method comprising mixing a mammalian sex hormone, sex hormone mimetic, sex hormone derivative, or mixtures thereof with a composition according to claim 1, and adjusting pH of the resulting mixture to a pH from about 3 to about 6.
49. The method of claim 48, wherein the pH is adjusted to a pH from about 5 to about 6.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6498097P | 1997-11-10 | 1997-11-10 | |
US60/064,980 | 1997-11-10 | ||
PCT/US1998/023750 WO1999024041A1 (en) | 1997-11-10 | 1998-11-09 | Penetration enhancing and irritation reducing systems |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2309688A1 CA2309688A1 (en) | 1999-05-20 |
CA2309688C true CA2309688C (en) | 2007-04-24 |
Family
ID=22059554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002309688A Expired - Fee Related CA2309688C (en) | 1997-11-10 | 1998-11-09 | Penetration enhancing and irritation reducing systems |
Country Status (17)
Country | Link |
---|---|
US (3) | US6319913B1 (en) |
EP (2) | EP1030668A4 (en) |
JP (2) | JP4139860B2 (en) |
KR (1) | KR100648536B1 (en) |
CN (1) | CN1172674C (en) |
AT (1) | ATE418988T1 (en) |
AU (1) | AU747041B2 (en) |
BR (1) | BR9814014B1 (en) |
CA (1) | CA2309688C (en) |
DE (1) | DE69840426D1 (en) |
DK (1) | DK1510213T3 (en) |
ES (1) | ES2318233T3 (en) |
IL (1) | IL136042A (en) |
NO (1) | NO20002422L (en) |
NZ (1) | NZ504423A (en) |
PT (1) | PT1510213E (en) |
WO (1) | WO1999024041A1 (en) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1172674C (en) * | 1997-11-10 | 2004-10-27 | 赛勒吉药物股份有限公司 | Penetration enhancing and irritation reducing systems |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
CN101305994A (en) * | 2000-04-26 | 2008-11-19 | 沃特森药物公司 | Minimizing adverse experience associated with oxybutynin therapy |
US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7897559B2 (en) * | 2000-06-29 | 2011-03-01 | Parks L Dean | Dermatological composition and kit containing avermectin compound for treating dermatological conditions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US8980290B2 (en) * | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
WO2002011768A1 (en) | 2000-08-03 | 2002-02-14 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
ATE460939T1 (en) * | 2000-08-30 | 2010-04-15 | Unimed Pharmaceuticals Llc | METHOD FOR TREATING ERECTIVE DISORDER AND INCREASE LIBIDO IN MEN |
BR0113649A (en) * | 2000-08-30 | 2004-07-20 | Unimed Pharmaceuticals Inc | Process for Increasing Testosterone and Related Steroid Concentrations in Women |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
JP5039252B2 (en) * | 2000-08-31 | 2012-10-03 | ユニメッド ファーマシューティカルズ,リミティド ライアビリティ カンパニー | Pharmaceutical compositions and methods for treating sexual dysfunction |
CZ20031761A3 (en) * | 2000-12-22 | 2004-01-14 | Dr. August Wolff Gmbh & Co. | Gel composition containing steroid and intended for treating hypogonadism |
EP1408896B1 (en) * | 2001-06-22 | 2016-01-20 | CPEX Pharmaceuticals, Inc. | Pharmaceutical composition |
AU2002333193A1 (en) * | 2001-08-15 | 2003-03-03 | Leo Pharma A/S | A pharmaceutical composition for dermal application |
US20030175329A1 (en) * | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
MXPA04006017A (en) | 2001-12-20 | 2005-06-08 | Femmepharma Inc | Vaginal delivery of drugs. |
CA2484164C (en) * | 2002-03-15 | 2009-12-29 | Unimed Pharmaceuticals, Inc. | Androgen pharmaceutical composition and method for treating depression |
TWI339122B (en) * | 2002-03-15 | 2011-03-21 | Lab Besins Iscovesco | Androgen pharmaceutical composition,kit containing the same and method for using the same |
MY139721A (en) | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
US6959640B2 (en) * | 2002-06-06 | 2005-11-01 | Omega Patents, L.L.C. | Device for magnetically treating materials and associated methods |
NZ537360A (en) | 2002-06-25 | 2006-09-29 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
MXPA05004278A (en) | 2002-10-25 | 2005-10-05 | Foamix Ltd | Cosmetic and pharmaceutical foam. |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
JP2006515026A (en) | 2003-01-02 | 2006-05-18 | フェムファーマ ホールディング カンパニー, インコーポレイテッド | Pharmaceutical preparations for the treatment of breast diseases and disorders |
US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
FR2851470B1 (en) | 2003-02-20 | 2007-11-16 | Besins Int Belgique | PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY |
EP1594545B1 (en) * | 2003-02-20 | 2008-11-12 | Besins International Belgique | Pharmaceutical composition for transdermal or transmucosal administration |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
US20050037040A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of urea and ammonium lactate |
US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
FR2856926B1 (en) * | 2003-07-02 | 2005-09-30 | Centre Nat Rech Scient | USE OF N-ALKANOLS AS ACTIVATORS OF THE CFTR CHANNEL |
US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
AU2004283431B2 (en) | 2003-10-10 | 2009-09-10 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
US20050244502A1 (en) * | 2004-04-28 | 2005-11-03 | Mathias Neil R | Composition for enhancing absorption of a drug and method |
US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
EP1802258A4 (en) | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
ES2607454T3 (en) | 2005-06-03 | 2017-03-31 | Acrux Dds Pty Ltd | Method and composition for transdermal testosterone delivery |
GB0518558D0 (en) * | 2005-09-12 | 2005-10-19 | Givaudan Sa | Improvements in or related to organic compounds |
TR201815853T4 (en) | 2005-10-12 | 2018-11-21 | Besins Healthcare Sarl | Testosterone gel for use in the treatment of hypogonadism. |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
CA2674078C (en) * | 2006-12-26 | 2012-03-20 | Femmepharma Holding Company, Inc. | Topical administration of danazol |
EP2106272A4 (en) | 2007-01-11 | 2011-05-04 | Acrux Dds Pty Ltd | Spreading implement |
WO2008089242A1 (en) * | 2007-01-16 | 2008-07-24 | Dermworx, Incorporated | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
US9283177B2 (en) * | 2007-01-16 | 2016-03-15 | Juventio, Llc | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
EP2242476A2 (en) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
MX2010007665A (en) * | 2008-05-21 | 2010-08-18 | Teikoku Pharma Usa Inc | Treatment of dysmenorrhea via transdermal administration of nonsteroidal anti-inflammatory drugs. |
CA2730787A1 (en) * | 2008-07-16 | 2010-01-21 | David M. Cohen | Topical drug delivery system |
CA2738970A1 (en) * | 2008-10-31 | 2010-05-06 | Moberg Derma Ab | Topical composition comprising a combination of at least two penetration enhancing agents |
DK2373305T3 (en) * | 2008-12-11 | 2017-05-15 | Besins Healthcare Lu Sarl | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS INCLUDING A SERM |
US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
EP2467127B1 (en) | 2009-08-21 | 2023-08-02 | Novan, Inc. | Topical gels |
MX359879B (en) | 2009-10-02 | 2018-10-12 | Foamix Pharmaceuticals Ltd | Topical tetracycline compositions. |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10080760B2 (en) | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
CN102309669B (en) * | 2010-07-08 | 2013-07-03 | 高健生 | Chinese medicinal preparation for treating allergic conjunctivitis |
US9642862B2 (en) | 2010-11-18 | 2017-05-09 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
CA2836405C (en) * | 2011-05-15 | 2021-09-07 | Trimel Biopharma Srl | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
BR112014000178A2 (en) | 2011-07-05 | 2017-02-07 | Novan Inc | topical compositions |
CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
CN102335390B (en) * | 2011-09-30 | 2013-01-02 | 王巍 | Lotion for treating facial eczema |
CN104302175B (en) | 2012-03-14 | 2017-04-12 | 诺万公司 | Nitric oxide releasing pharmaceutical compositions |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US9855211B2 (en) * | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
KR102321169B1 (en) | 2013-08-08 | 2021-11-02 | 노반, 인크. | Topical compositions and methods of using the same |
USD749225S1 (en) | 2013-11-26 | 2016-02-09 | Acrux Dds Pty Ltd | Topical spreading applicator |
USD750788S1 (en) | 2013-11-26 | 2016-03-01 | Acrux Dds Pty Ltd | Topical spreading applicator |
US8785426B1 (en) * | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
ES2807200T3 (en) | 2014-07-11 | 2021-02-22 | Novan Inc | Topical antiviral compositions and procedures for their use |
EP3177262A4 (en) | 2014-08-08 | 2018-04-18 | Novan Inc. | Topical emulsions |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
US20170014417A1 (en) | 2015-07-14 | 2017-01-19 | Lipp Life Sciences Llc | Pharmaceutical administration system for the transdermal application of vardenafil |
CN107949389A (en) * | 2015-09-30 | 2018-04-20 | 富士胶片株式会社 | Percutaneous absorbtion composition |
WO2017151905A1 (en) | 2016-03-02 | 2017-09-08 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
EP3442502A4 (en) | 2016-04-13 | 2019-11-06 | Novan, Inc. | Compositions, systems, kits, and methods for treating an infection |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
CN112165935A (en) | 2018-03-01 | 2021-01-01 | 诺万公司 | Nitric oxide-releasing suppository and method of use |
EP3801732A4 (en) | 2018-05-29 | 2022-04-27 | Morningside Venture Investments Limited | Drug delivery methods and systems |
WO2020084548A1 (en) | 2018-10-26 | 2020-04-30 | Viramal Limited | Mucoadhesive gel composition |
KR20240004764A (en) | 2021-04-30 | 2024-01-11 | 칼리버 임뮤노쎄라퓨틱스, 인크. | Oncolytic viruses for modified MHC expression |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US175329A (en) * | 1876-03-28 | Improvement in processes of preserving burial-cases | ||
CA1165240A (en) | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
JPS59134710A (en) | 1983-01-21 | 1984-08-02 | Suntory Ltd | Hair tonic from fermentation product |
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
JPS6067409A (en) | 1983-09-22 | 1985-04-17 | Suntory Ltd | Hair cosmetic |
US4743588A (en) * | 1984-06-13 | 1988-05-10 | Allergan Pharmaceuticals, Inc. | Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents |
US5196410A (en) * | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
EP0267617B1 (en) * | 1986-11-14 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
CA1331137C (en) * | 1988-02-29 | 1994-08-02 | Pfizer, Inc. | Transdermal flux enhancing compositions |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4855294A (en) | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
CA2004203A1 (en) * | 1988-12-01 | 1990-06-01 | Sharad K. Govil | Compositions for transdermal delivery of estradiol |
DE68927675T2 (en) * | 1989-08-23 | 1997-07-10 | Philips Electronics Nv | Method for correcting network weighting factors in a multilayer perceptron device and such a device with means for carrying out this method |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
KR100256715B1 (en) * | 1991-08-26 | 2000-05-15 | 스티븐 에프. 웨인스톡 | Composition for the sublingual or buccal administration of therapeutic agents |
JPH08501529A (en) * | 1992-06-11 | 1996-02-20 | セラテック・インコーポレイテッド | Use of glycerin to alleviate skin-penetrating drug administration |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
AU2345695A (en) * | 1994-04-28 | 1995-11-29 | F. Hoffmann-La Roche Ag | Pharmaceutical composition for transdermal delivery |
US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
AU1429697A (en) * | 1995-12-29 | 1997-07-28 | Cygnus, Inc. | Systems and methods for the transdermal administration of androgenic agents |
IT1283102B1 (en) * | 1996-06-06 | 1998-04-07 | Permatec Nv | THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES |
US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
JP2001503062A (en) * | 1996-10-30 | 2001-03-06 | セラテック・インコーポレーテッド | Salts of fatty acid esters of lactic acid as permeation enhancers |
CN1172674C (en) * | 1997-11-10 | 2004-10-27 | 赛勒吉药物股份有限公司 | Penetration enhancing and irritation reducing systems |
US6465009B1 (en) | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
US20030175329A1 (en) | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
-
1998
- 1998-11-09 CN CNB988130491A patent/CN1172674C/en not_active Expired - Fee Related
- 1998-11-09 IL IL13604298A patent/IL136042A/en not_active IP Right Cessation
- 1998-11-09 BR BRPI9814014-0A patent/BR9814014B1/en not_active IP Right Cessation
- 1998-11-09 EP EP98956663A patent/EP1030668A4/en not_active Withdrawn
- 1998-11-09 DE DE69840426T patent/DE69840426D1/en not_active Expired - Lifetime
- 1998-11-09 AT AT04028426T patent/ATE418988T1/en active
- 1998-11-09 DK DK04028426T patent/DK1510213T3/en active
- 1998-11-09 PT PT04028426T patent/PT1510213E/en unknown
- 1998-11-09 KR KR1020007005094A patent/KR100648536B1/en active IP Right Grant
- 1998-11-09 AU AU13132/99A patent/AU747041B2/en not_active Ceased
- 1998-11-09 WO PCT/US1998/023750 patent/WO1999024041A1/en active IP Right Grant
- 1998-11-09 EP EP04028426A patent/EP1510213B1/en not_active Revoked
- 1998-11-09 JP JP2000520133A patent/JP4139860B2/en not_active Expired - Fee Related
- 1998-11-09 CA CA002309688A patent/CA2309688C/en not_active Expired - Fee Related
- 1998-11-09 US US09/189,090 patent/US6319913B1/en not_active Expired - Lifetime
- 1998-11-09 ES ES04028426T patent/ES2318233T3/en not_active Expired - Lifetime
- 1998-11-09 NZ NZ504423A patent/NZ504423A/en not_active IP Right Cessation
-
2000
- 2000-05-10 NO NO20002422A patent/NO20002422L/en not_active Application Discontinuation
-
2001
- 2001-09-24 US US09/963,287 patent/US6579865B2/en not_active Expired - Lifetime
-
2003
- 2003-03-12 US US10/389,715 patent/US7157097B2/en not_active Expired - Lifetime
-
2004
- 2004-10-28 JP JP2004313201A patent/JP2005047932A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BR9814014A (en) | 2000-09-26 |
AU747041C (en) | 1999-05-31 |
IL136042A (en) | 2005-12-18 |
KR100648536B1 (en) | 2006-11-24 |
CN1285749A (en) | 2001-02-28 |
US20020058650A1 (en) | 2002-05-16 |
US6319913B1 (en) | 2001-11-20 |
NO20002422L (en) | 2000-06-21 |
EP1030668A1 (en) | 2000-08-30 |
EP1030668A4 (en) | 2002-09-25 |
EP1510213A3 (en) | 2005-03-23 |
DK1510213T3 (en) | 2009-03-23 |
US20030166625A1 (en) | 2003-09-04 |
EP1510213A2 (en) | 2005-03-02 |
ES2318233T3 (en) | 2009-05-01 |
AU1313299A (en) | 1999-05-31 |
ATE418988T1 (en) | 2009-01-15 |
AU747041B2 (en) | 2002-05-09 |
JP4139860B2 (en) | 2008-08-27 |
BR9814014B1 (en) | 2014-10-07 |
NO20002422D0 (en) | 2000-05-10 |
JP2001522804A (en) | 2001-11-20 |
PT1510213E (en) | 2009-02-12 |
CN1172674C (en) | 2004-10-27 |
IL136042A0 (en) | 2001-05-20 |
JP2005047932A (en) | 2005-02-24 |
NZ504423A (en) | 2003-04-29 |
EP1510213B1 (en) | 2008-12-31 |
WO1999024041A1 (en) | 1999-05-20 |
US7157097B2 (en) | 2007-01-02 |
US6579865B2 (en) | 2003-06-17 |
KR20010031984A (en) | 2001-04-16 |
DE69840426D1 (en) | 2009-02-12 |
CA2309688A1 (en) | 1999-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2309688C (en) | Penetration enhancing and irritation reducing systems | |
US7425340B2 (en) | Permeation enhancing compositions for anticholinergic agents | |
JP4610741B2 (en) | An anhydrous topical skin preparation | |
AU757086B2 (en) | Topical compositions for prostaglandin E1 delivery | |
EP0513832A1 (en) | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products | |
JPH082801B2 (en) | Transdermal absorption enhancer and skin external preparation | |
AU633207B2 (en) | Compositions comprising cytotoxic agent and permeation enhancers | |
JPH06256218A (en) | Medicine for external use | |
MXPA00004513A (en) | Penetration enhancing and irritation reducing systems | |
US5183665A (en) | Composition for percutaneous administration and method for enhancing percutaneous absorption of a physiologically active ingredient empolying the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20161109 |